Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

<p>Supplementary Figure 1</p>

Salvato in:

Dettagli Bibliografici
Autore principale:	Vishwajith Sridharan (15047154) (author)
Altri autori:	Azfar Neyaz (15047157) (author), Abhijit Chogule (15047160) (author), Islam Baiev (15047163) (author), Stephanie Reyes (15047166) (author), Emily G. Barr Fritcher (15047169) (author), Jochen K. Lennerz (15014703) (author), William Sukov (15047172) (author), Benjamin Kipp (15047175) (author), David T. Ting (15018716) (author), Vikram Deshpande (15047178) (author), Lipika Goyal (15047181) (author)
Pubblicazione:	2025
Soggetti:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Gastrointestinal Cancers Immunotherapy Checkpoint blockade Precision Medicine Translational Research
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
di: Evan C. Chen (15054014)
Pubblicazione: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
di: Evan C. Chen (15054014)
Pubblicazione: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
di: Evan C. Chen (15054014)
Pubblicazione: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
di: Evan C. Chen (15054014)
Pubblicazione: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
di: Evan C. Chen (15054014)
Pubblicazione: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
di: Evan C. Chen (15054014)
Pubblicazione: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
di: Jiachun Su (16990970)
Pubblicazione: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
di: Joel R. Eisner (15132120)
Pubblicazione: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
di: Joel R. Eisner (15132120)
Pubblicazione: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
di: Joel R. Eisner (15132120)
Pubblicazione: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
di: Nicholas T. Younger (14956251)
Pubblicazione: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
di: Nicholas T. Younger (14956251)
Pubblicazione: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
di: Nicholas T. Younger (14956251)
Pubblicazione: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
di: Nicholas T. Younger (14956251)
Pubblicazione: (2025)

Genetic variation and mRNA expression of the <i>ELOVL6</i> and <i>CRTC2</i> genes in Kalmyk cattle
di: Nurlybay Kazhgaliyev (9904228)
Pubblicazione: (2025)

APP deficiency did not affect the mRNA level of <i>Scn8a</i> in cerebellar PCs.
di: Miao-Jin Ji (22676552)
Pubblicazione: (2025)

Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
di: Natalie C. Fisher (15046025)
Pubblicazione: (2025)

Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
di: Natalie C. Fisher (15046025)
Pubblicazione: (2025)

Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
di: Natalie C. Fisher (15046025)
Pubblicazione: (2025)

Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
di: Natalie C. Fisher (15046025)
Pubblicazione: (2025)

Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
di: Natalie C. Fisher (15046025)
Pubblicazione: (2025)

Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
di: Natalie C. Fisher (15046025)
Pubblicazione: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
di: Carlotta Antoniotti (15352506)
Pubblicazione: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
di: Carlotta Antoniotti (15352506)
Pubblicazione: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
di: Carlotta Antoniotti (15352506)
Pubblicazione: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
di: Katie E. Hebron (15046889)
Pubblicazione: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
di: Katie E. Hebron (15046889)
Pubblicazione: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
di: Katie E. Hebron (15046889)
Pubblicazione: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
di: Katie E. Hebron (15046889)
Pubblicazione: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
di: Katie E. Hebron (15046889)
Pubblicazione: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
di: Katie E. Hebron (15046889)
Pubblicazione: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
di: Katie E. Hebron (15046889)
Pubblicazione: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
di: Ruth Flümann (15123900)
Pubblicazione: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
di: Chong Kin Liam (15331321)
Pubblicazione: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
di: Chong Kin Liam (15331321)
Pubblicazione: (2025)

Cannot write session to /tmp/vufind_sessions/sess_vofsg9v8fra071tnvpthfogb7r